Reuters logo
4 months ago
BRIEF-Summit to extend ongoing trial of Ezutromid in patients with Duchenne disorder
March 27, 2017 / 11:34 AM / 4 months ago

BRIEF-Summit to extend ongoing trial of Ezutromid in patients with Duchenne disorder

1 Min Read

March 27 (Reuters) - Summit Therapeutics Plc

* Summit Therapeutics Plc - decision follows interim safety review by phaseout dmd's independent data monitoring committee

* Summit to extend ongoing phaseout dmd clinical trial of Ezutromid in patients with dmd

* Summit Therapeutics Plc - will proceed with planned extension phase of phaseout dmd

* Summit Therapeutics Plc - now applied for regulatory approval to extend phaseout dmd from uk medicines, healthcare products regulatory agency, ethics committee

* Summit Therapeutics Plc - in addition to extension phase of trial, regulatory submissions also include addition of a safety arm

* Summit Therapeutics - safety arm to allow enrolment of patients from phase 1 clinical trials of ezutromid but didn't meet inclusion criteria for phaseout dmd Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below